BACKGROUND: Pegaspargase (PEG-ASP) is essential chemotherapy for acute lymphoblastic leukemia (ALL). Since changing to intravenous (IV) administration from intramuscular (IM), an increased number of allergic reactions have been anecdotally noted at our institution. This study compares the rate and severity of allergic reactions in children receiving IM or IV PEG-ASP. METHODS: We performed a retrospective chart review of patients treated with IV or IM PEG-ASP at The Hospital for Sick Children, Toronto, Canada, from March 1, 2010 to January 1, 2012. The incidence and severity of allergic reactions attributed to PEG-ASP were documented. Patient age, sex, route of PEG-ASP administration, disease (risk group and lineage) and mean time interval between PEG-ASP doses were evaluated as possible risk factors for allergic reaction. RESULTS: A total of 109 patients were included. There were 14 (35 %) allergic reactions among 40 patients who received IV, compared with eight (12 %) of the 69 who received IM [odds ratio (OR) 4.11, 95 % confidence interval (CI) 1.54-10.97, p = 0.005]. In multivariable logistic regression adjusting for disease risk group, route (IV vs. IM) remained independently significant (p = 0.011). Patients with standard-risk ALL had a lower risk of experiencing an allergic reaction associated with PEG-ASP compared with patients in high-risk disease risk groups (collectively referred to as "other"; 11 vs. 31 %, OR 3.36, 95 % CI 1.16-9.72, p = 0.025). CONCLUSIONS: IV PEG-ASP is associated with a significantly higher rate of allergic reactions than IM. The clinical preference for IV PEG-ASP may warrant re-evaluation.
BACKGROUND:Pegaspargase (PEG-ASP) is essential chemotherapy for acute lymphoblastic leukemia (ALL). Since changing to intravenous (IV) administration from intramuscular (IM), an increased number of allergic reactions have been anecdotally noted at our institution. This study compares the rate and severity of allergic reactions in children receiving IM or IV PEG-ASP. METHODS: We performed a retrospective chart review of patients treated with IV or IM PEG-ASP at The Hospital for Sick Children, Toronto, Canada, from March 1, 2010 to January 1, 2012. The incidence and severity of allergic reactions attributed to PEG-ASP were documented. Patient age, sex, route of PEG-ASP administration, disease (risk group and lineage) and mean time interval between PEG-ASP doses were evaluated as possible risk factors for allergic reaction. RESULTS: A total of 109 patients were included. There were 14 (35 %) allergic reactions among 40 patients who received IV, compared with eight (12 %) of the 69 who received IM [odds ratio (OR) 4.11, 95 % confidence interval (CI) 1.54-10.97, p = 0.005]. In multivariable logistic regression adjusting for disease risk group, route (IV vs. IM) remained independently significant (p = 0.011). Patients with standard-risk ALL had a lower risk of experiencing an allergic reaction associated with PEG-ASP compared with patients in high-risk disease risk groups (collectively referred to as "other"; 11 vs. 31 %, OR 3.36, 95 % CI 1.16-9.72, p = 0.025). CONCLUSIONS: IV PEG-ASP is associated with a significantly higher rate of allergic reactions than IM. The clinical preference for IV PEG-ASP may warrant re-evaluation.
Authors: Joanne Kurtzberg; Barbara Asselin; Mark Bernstein; George R Buchanan; Brad H Pollock; Bruce M Camitta Journal: J Pediatr Hematol Oncol Date: 2011-12 Impact factor: 1.289
Authors: Dan Douer; Henry Yampolsky; Lewis J Cohen; Kristy Watkins; Alexandra M Levine; Antonia P Periclou; Vassilios I Avramis Journal: Blood Date: 2007-04-01 Impact factor: 22.113
Authors: Lewis B Silverman; Jeffrey G Supko; Kristen E Stevenson; Christina Woodward; Lynda M Vrooman; Donna S Neuberg; Barbara L Asselin; Uma H Athale; Luis Clavell; Peter D Cole; Kara M Kelly; Caroline Laverdière; Bruno Michon; Marshall Schorin; Cindy L Schwartz; Jane E O'Brien; Harvey J Cohen; Stephen E Sallan Journal: Blood Date: 2009-12-10 Impact factor: 22.113
Authors: Jonathan K Armstrong; Georg Hempel; Susanne Koling; Linda S Chan; Timothy Fisher; Herbert J Meiselman; George Garratty Journal: Cancer Date: 2007-07-01 Impact factor: 6.860
Authors: Christian A Fernandez; Colton Smith; Wenjian Yang; Mihir Daté; Donald Bashford; Eric Larsen; W Paul Bowman; Chengcheng Liu; Laura B Ramsey; Tamara Chang; Victoria Turner; Mignon L Loh; Elizabeth A Raetz; Naomi J Winick; Stephen P Hunger; William L Carroll; Suna Onengut-Gumuscu; Wei-Min Chen; Patrick Concannon; Stephen S Rich; Paul Scheet; Sima Jeha; Ching-Hon Pui; William E Evans; Meenakshi Devidas; Mary V Relling Journal: Blood Date: 2014-06-26 Impact factor: 22.113
Authors: Yiwei Liu; Colton A Smith; John C Panetta; Wenjian Yang; Lauren E Thompson; Jacob P Counts; Alejandro R Molinelli; Deqing Pei; Nancy M Kornegay; Kristine R Crews; Hope Swanson; Cheng Cheng; Seth E Karol; William E Evans; Hiroto Inaba; Ching-Hon Pui; Sima Jeha; Mary V Relling Journal: J Clin Oncol Date: 2019-06-12 Impact factor: 44.544
Authors: Stacy L Cooper; David J Young; Caitlin J Bowen; Nicole M Arwood; Sarah G Poggi; Patrick A Brown Journal: Pediatr Blood Cancer Date: 2019-05-16 Impact factor: 3.167
Authors: Sara Zarnegar-Lumley; Cosby A Stone; Christine M Smith; Laura L Hall; Kate E Luck; Grace Koo; Jessica H Plager; Elizabeth J Phillips; Debra L Friedman Journal: Pediatr Blood Cancer Date: 2022-03-30 Impact factor: 3.838
Authors: Zhao-Hua Zhou; Cosby A Stone; Baruch Jakubovic; Elizabeth J Phillips; Gordon Sussman; JuMe Park; Uyen Hoang; Susan L Kirshner; Robert Levin; Steven Kozlowski Journal: J Allergy Clin Immunol Pract Date: 2020-11-17